Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Neurourol Urodyn. 2023 Jun 3;42(6):1214–1226. doi: 10.1002/nau.25222

Table 3.

Most invasive level of treatment, number of participants n (%)

Prior to or at baseline During follow-up

No treatment 90 (26%) 71 (20%)
Level 1: BT 182 (52%) 84 (24%)
Level 2: PT 38 (11%) 79 (23%)
Level 3: OAB medications 35 (10%) 91 (26%)
Level 4 4 (1.2%) 24 (7%)
PTNS 1 (0.3%) 3 (1%)
BTX 2 (0.6%) 10 (3%)
SNM 1 (0.3%) 11 (3%)

BT, behavioral therapy; PT, pelvic floor physical therapy; OAB, overactive bladder; PTNS, percutaneous tibial nerve stimulation; BTX, intradetrusor onabotulinumtoxinA; SNM, sacral neuromodulation